While valuations across the pharmaceutical industry have soared this year -- with shares of diversified giants like Merck (NYSE: MRK ) and Pfizer up significantly -- Bristol-Myers Squibb (NYSE: BMY ) in particular has been on a tear recently. In the last 12 months, its shares are up a whopping 40%. However, despite all of the promising drugs that the company is developing in clinical trials, is there any upside left in this stock today? In the following video, analysts David Williamson and Max Macaluso discuss three reasons to consider selling Bristol-Myers.
3 stocks you can own forever
Every good investor wants to build that perfect portfolio that they can set and forget forever. Fortunately, it's easier than anyone ever knew. We've uncovered the pillars of such a portfolio today and we're willing to share The Motley Fool's 3 Stocks to Own Forever. Simply stated, we think they're the best stocks for true long-term investors to know about, and you can uncover them for free today, instantly; just click here now.